HSP72 and Bortezomib in Urothelial Cancer
The interplay between proteasome inhibition and cellular stress response pathways is a critical determinant of therapeutic efficacy in urothelial carcinoma. Bortezomib, a reversible proteasome inhibitor, induces endoplasmic reticulum (ER) stress…